Literature DB >> 18571090

Clinical experience with intraoperative floppy-iris syndrome. Results of the 2008 ASCRS member survey.

David F Chang1, Rosa Braga-Mele, Nick Mamalis, Samuel Masket, Kevin M Miller, Louis D Nichamin, Richard B Packard, Mark Packer.   

Abstract

According to an online survey, most members of the American Society of Cataract and Refractive Surgery believe that tamsulosin makes cataract surgery more difficult (95%) and increases the risks of surgery (77%). Commonly reported complications of intraoperative floppy-iris syndrome (IFIS) were significant iris trauma and posterior capsule rupture, with 52% and 23% of respondents, respectively, reporting these complications at a higher rate than in non-IFIS eyes. There was no single preferred surgical method for managing IFIS; 33% of respondents routinely used multiple strategies. Of respondents with sufficient experience, 90% believe that IFIS is more likely with tamsulosin than with nonspecific alpha1-antagonists. Ninety-one percent believe that physicians prescribing alpha1-antagonists should become better educated about IFIS, and 59% would recommend a pretreatment ophthalmic evaluation for patients with cataracts or decreased vision. If they themselves had mildly symptomatic cataracts, 64% of respondents would avoid taking tamsulosin or would have their cataract removed first.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571090     DOI: 10.1016/j.jcrs.2008.04.014

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  23 in total

1.  Correlation between urological alpha1-AR antagonist medication and changed intraoperative iris behavior.

Authors:  Karin Horvath; Florina Vultur
Journal:  Int Ophthalmol       Date:  2011-01-29       Impact factor: 2.031

2.  Awareness of intraoperative floppy-iris syndrome among primary care physicians.

Authors:  E Lauren Doss; Michael B Potter; David F Chang
Journal:  J Cataract Refract Surg       Date:  2014-02-22       Impact factor: 3.351

3.  Practice patterns and opinions in the management of recurrent or chronic herpes zoster ophthalmicus.

Authors:  Aileen Sy; Stephen D McLeod; Elisabeth J Cohen; Todd P Margolis; Mark J Mannis; Thomas M Lietman; Nisha R Acharya
Journal:  Cornea       Date:  2012-07       Impact factor: 2.651

4.  Risk factors for intraoperative floppy iris syndrome: a prospective study.

Authors:  I P Chatziralli; V Peponis; E Parikakis; A Maniatea; E Patsea; P Mitropoulos
Journal:  Eye (Lond)       Date:  2016-07-01       Impact factor: 3.775

5.  Impact of tamsulosin exposure on late complications following cataract surgery: retrospective cohort study.

Authors:  Julio González-Martín-Moro; Julio José González-López; Fernando Gómez-Sanz; Jesús Zarallo-Gallardo; Rosario Cobo-Soriano
Journal:  Int Ophthalmol       Date:  2013-10-25       Impact factor: 2.031

6.  Intraoperative floppy iris syndrome and its association with various concurrent medications, bulbus length, patient age and gender.

Authors:  Michael Wahl; Saskia M Tipotsch-Maca; Pia V Vecsei-Marlovits
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-19       Impact factor: 3.117

7.  Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery.

Authors:  Zuhair K Al-Hussaini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

8.  Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates.

Authors:  Anjana Haridas; Marina Syrimi; Basel Al-Ahmar; Melanie Hingorani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-19       Impact factor: 3.117

9.  [Managing complications in intraoperative floppy iris syndrome].

Authors:  D M Handzel; S Rausch; T Kälble; S Briesen
Journal:  Ophthalmologe       Date:  2013-04       Impact factor: 1.059

10.  [Pharmacotherapy of urinary incontinence in the elderly].

Authors:  K F Becher
Journal:  Internist (Berl)       Date:  2016-04       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.